Dynamic contrast-enhanced MRI perfusion quantification in hepatocellular carcinoma: comparison of gadoxetate disodium and gadobenate dimeglumine

Simple item page
dc.coverageDOI: 10.1007/s00330-021-08068-5
dc.creatorStocker, Daniel
dc.creatorHectors, Stefanie
dc.creatorBane, Octavia
dc.creatorVietti-Violi, Naik
dc.creatorSaid, Daniela
dc.creatorKennedy, Paul
dc.creatorCuevas, Jordan
dc.creatorCunha, Guilherme M.
dc.creatorSirlin, Claude B.
dc.creatorFowler, Kathryn J.
dc.creatorLewis, Sara
dc.creatorTaouli, Bachir
dc.date2021
dc.date.accessioned2025-11-18T19:52:08Z
dc.date.available2025-11-18T19:52:08Z
dc.description<p>Objectives: (1) To assess the quality of the arterial input function (AIF) during dynamic contrast-enhanced (DCE) MRI of the liver and (2) to quantify perfusion parameters of hepatocellular carcinoma (HCC) and liver parenchyma during the first 3 min post-contrast injection with DCE-MRI using gadoxetate disodium compared to gadobenate dimeglumine (Gd-BOPTA) in different patient populations. Methods: In this prospective study, we evaluated 66 patients with 83 HCCs who underwent DCE-MRI, using gadoxetate disodium (group 1, n = 28) or Gd-BOPTA (group 2, n = 38). AIF qualitative and quantitative features were assessed. Perfusion parameters (based on the initial 3 min post-contrast) were extracted in tumours and liver parenchyma, including model-free parameters (time-to-peak enhancement (TTP), time-to-washout) and modelled parameters (arterial flow (F<sub>a</sub>), portal venous flow (F<sub>p</sub>), total flow (F<sub>t</sub>), arterial fraction, mean transit time (MTT), distribution volume (DV)). In addition, lesion-to-liver contrast ratios (LLCRs) were measured. Fisher’s exact tests and Mann-Whitney U tests were used to compare the two groups. Results: AIF quality, modelled and model-free perfusion parameters in HCC were similar between the 2 groups (p = 0.054–0.932). Liver parenchymal flow was lower and liver enhancement occurred later in group 1 vs group 2 (F<sub>p</sub>, p = 0.002; F<sub>t</sub>, p = 0.001; TTP, MTT, all p &lt; 0.001), while there were no significant differences in tumour LLCR (max. positive LLCR, p = 0.230; max. negative LLCR, p = 0.317). Conclusion: Gadoxetate disodium provides comparable AIF quality and HCC perfusion parameters compared to Gd-BOPTA during dynamic phases. Despite delayed and decreased liver enhancement with gadoxetate disodium, LLCRs were equivalent between contrast agents, indicating similar tumour conspicuity. Key Points: • Arterial input function quality, modelled, and model-free dynamic parameters measured in hepatocellular carcinoma are similar in patients receiving gadoxetate disodium or gadobenate dimeglumine during the first 3 min post injection. • Gadoxetate disodium and gadobenate dimeglumine show similar lesion-to-liver contrast ratios during dynamic phases in patients with HCC. • There is lower portal and lower total hepatic flow and longer hepatic mean transit time and time-to-peak with gadoxetate disodium compared to gadobenate dimeglumine.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/fc04aadf-a612-4f77-b138-21a1c483bbba
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/57557
dc.languageeng
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.sourcevol.31 (2021) nr.12 p.9306-9315
dc.subjectCarcinoma, hepatocellular
dc.subjectGadobenate dimeglumine
dc.subjectGadoxetate
dc.subjectLiver neoplasms
dc.subjectMagnetic resonance imaging
dc.titleDynamic contrast-enhanced MRI perfusion quantification in hepatocellular carcinoma: comparison of gadoxetate disodium and gadobenate dimeglumineeng
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
PURE